Reckitt Benckiser Group plc (RBGPF)
| Market Cap | 41.33B -20.0% |
| Revenue (ttm) | 18.09B -3.1% |
| Net Income | 3.82B +115.6% |
| EPS | 5.88 +121.8% |
| Shares Out | n/a |
| PE Ratio | 10.83 |
| Forward PE | 14.18 |
| Dividend | 1.21 (1.85%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | 225 |
| Open | 65.71 |
| Previous Close | 65.99 |
| Day's Range | 65.28 - 65.71 |
| 52-Week Range | 58.67 - 90.71 |
| Beta | 0.25 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 23, 2026 |
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under MegaRed, Airborne, Digestive-Advantage, Movefree, and neuriva names; stain removal under... [Read more]
Financial Performance
In 2025, Reckitt Benckiser Group's revenue was 14.21 billion, an increase of 0.25% compared to the previous year's 14.17 billion. Earnings were 3.18 billion, an increase of 123.14%.
Financial numbers in GBP Financial StatementsNews
Lysol and Mucinex Maker Reckitt Expands U.S. Manufacturing
The maker of Lysol and Mucinex is doubling down on U.S. manufacturing and product development, the WSJ Logistics Report's Liz Young writes. Consumer-goods seller Reckitt Benckiser Group says it plans ...
Reckitt Benckiser to invest $400M more in U.S. over four years, WSJ reports
Mucinex and Lysol maker Reckitt Benckiser (RBGLY) plans to invest about $400M more over the next four years in the U.S. to speed up product innovation and demand response, The…
Mucinex Maker Bets $400 Million More on U.S. Supply Chain
Reckitt expands a North Carolina manufacturing plant and a New Jersey campus to meet shifts in consumer demand.
Reckitt Benckiser Group Transcript: Barclays 19th Annual Global Consumer Conference
Management highlighted strong legal wins, robust innovation, and high single-digit growth in emerging markets. Pricing actions are landing well in developing markets, while Europe and the U.S. remain challenging. Mead Johnson continues to attract interest, and operational efficiency is improving through cost initiatives.
Reckitt Benckiser downgraded to Neutral from Outperform at BNP Paribas
BNP Paribas downgraded Reckitt Benckiser (RBGLY) to Neutral from Outperform with a 5,800 GBp price target
Reckitt Benckiser upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Reckitt Benckiser (RBGLY) to Overweight from Neutral with a price target of 6,500 GBp, up from 5,800 GBp. The firm believes the company is closer to settling its…
3 Cheap International Stocks to Buy
These stocks have economic moats and look attractive today.
Reckitt Benckiser’s Mead Johnson faces first bellwether trial over Enfamil
Reckitt Benckiser (RBGLY) subsidiary, Mead Johnson is facing the first bellwether as part of a multidistrict litigation in the US District Court for the Northern District of Illinois over its…
First Bellwether Trial Today Against Reckitt Benckiser's Mead Johnson in NEC Baby Formula MDL Led by Levin Papantonio
PENSACOLA, Fla.--(BUSINESS WIRE)--Reckitt Benckiser (LON: RKT) subsidiary, Mead Johnson is facing the first bellwether today as part of a multidistrict litigation (MDL) in the US District Court for th...
Reckitt Announces Expiration and Results of Any and All Tender Offer and Consent Solicitation for Mead Johnson Nutrition Company Notes due 2044
SLOUGH, United Kingdom, Aug. 14, 2026 /PRNewswire/ -- Reckitt Benckiser Group plc ("Reckitt") (LSE: RKT) announced today (i) the expiration and results of its wholly-owned subsidiary, Mead Johnson Nut...
Reckitt Benckiser Group H1 Earnings Call Highlights
Reckitt Benckiser Group LON: RKT reported accelerating sales growth in the second quarter of 2026, supported by innovation, emerging-market demand and a return to growth in North America, while mainta...
Reckitt Benckiser Group Earnings Call Transcript: H1 2026
Group delivered 2.6% like-for-like net revenue growth in H1 2026, with Q2 accelerating to 4.7%. Innovation, emerging markets, and portfolio focus drove performance, while over GBP 3 billion was returned to shareholders. Full-year guidance for 4%-5% growth and margin targets remain unchanged.
Reckitt Benckiser Group Quarterly report: H1 2026
Reckitt Benckiser Group has published its H1 2026 quarterly earnings report on July 29, 2026.
Reckitt Benckiser Group Slides: H1 2026
Reckitt Benckiser Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 29, 2026.
Lysol Maker Reckitt Issues New $664 Million Share Buyback
The Lysol, Mucinex and Durex-condom maker issued a new share buyback program after reporting 4.7% like-for-like net revenue, bolstered by growth in emerging markets.
Reckitt beats second-quarter sales estimates on emerging markets strength
Dettol maker Reckitt beat second-quarter sales growth estimates and reaffirmed its annual forecast on Wednesday, as strong demand in China, India and other emerging markets helped offset weakness in...
Lysol Maker Reckitt to Offload Sanctions-Hit Russian Hygiene Business
The deal with Russia's Arnest Management—which manufactures cosmetics and household goods—is expected to complete during the second half of 2026.
UK's Reckitt to sell Russian hygiene business
Britain's Reckitt Benckiser Group said on Friday that it has agreed to divest its Russian hygiene business to Arnest Management LLC for an undisclosed sum.
Reckitt Benckiser upgraded to Buy from Hold at Jefferies
Jefferies analyst David Hayes upgraded Reckitt Benckiser (RBGLY) to Buy from Hold with a price target of 5,900 GBp, up from 5,600 GBp. Sanctions on Russia Household products, regulatory intervention…
Missouri jury sides with Enfamil maker Mead Johnson in case over preterm baby formula
A jury in St. Louis on Thursday rejected claims that Reckitt unit Mead Johnson's specialized formula for preterm babies was to blame for causing an infant's dangerous bowel disease.
Reckitt Benckiser price target lowered to 5,400 GBp at Deutsche Bank
Deutsche Bank analyst Tom Sykes lowered the firm’s price target on Reckitt Benckiser (RBGLY) to 5,400 GBp from 5,430 GBp and keeps a Hold rating on the shares. Published first…
Reckitt Benckiser price target lowered to 5,800 GBp at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Reckitt Benckiser (RBGLY) to 5,800 GBp from 6,200 GBp and keeps an Overweight rating on the shares.
Reckitt Benckiser Bets on AI to Speed Innovation and Boost Growth
Reckitt Benckiser Group LON: RKT executives used an investor “Focus On” event to outline how the company is applying digital science, artificial intelligence and predictive modeling across its innovat...
Reckitt Benckiser Group Transcript: Investor update
Digital science and AI are transforming all stages of innovation, driving faster, larger, and more successful product launches, with tangible impacts on growth, cost savings, and sustainability. Proprietary data, advanced platforms, and a global upskilling effort underpin a robust, differentiated pipeline and operational efficiency.
Reckitt Benckiser price target lowered to 6,200 GBp from 7,000 GBp at Citi
Citi lowered the firm’s price target on Reckitt Benckiser (RBGLY) to 6,200 GBp from 7,000 GBp and keeps a Buy rating on the shares.